Dan Lemaitre is President and CEO of White Pine Medical, a medical device investment vehicle backed by Essex Woodlands, the largest dedicated health care growth capital fund in the U.S. Mr. Lemaitre is also Chairman of Bioventus, a North Carolina based medical device company will annual revenue of $250 million and more than 500 employees worldwide.
Prior to White Pine Medical, Mr. Lemaitre served as President and CEO of CoreValve which was acquired in 2009. CoreValve’s unique self-expanding percutaneous aortic valve has been implanted in more than 30,000 patients since obtaining CE Mark in 2007. At the time of acquisition end-market revenue was annualizing at a $100 million run-rate. Dan led negotiations that resulted in the sale of CoreValve in a deal worth $800 million.
Prior to joining CoreValve, Dan was Senior Vice President at Medtronic where he headed-up strategic planning and corporate development and was a member of the executive and operating committees. He spent 28 years as an investment analyst including 18 years with SG Cowen, where he was a managing director and led the health care research team. In 1999, Dan moved his team to Merrill Lynch where he headed-up the medical technology effort for six years. During his Wall Street tenure, Dan was named to Institutional Investor’s All American research team for 19 consecutive years, capturing first place honors 8 times as the top ranked medical device analyst in the country.
Dan has a BA in Economics (1976) from Bethany College (West Virginia) and an MBA (1978) from Bowling Green State University in Ohio. He earned a Chartered Financial Analyst (CFA) in 1982. Lemaitre serves on the board and audit committee of Endologix (NASDAQ: ELGX) and Globus Medical (NYSE: GMED) where he serves on the audit and compensation committees.